• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer.

作者信息

Han Yongzheng, Xie Wenlong, Wu Guangzhen

机构信息

Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China.

Department of Ultrasound, the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China.

出版信息

J Transl Med. 2025 Jul 29;23(1):851. doi: 10.1186/s12967-025-06731-9.

DOI:10.1186/s12967-025-06731-9
PMID:40731358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12309058/
Abstract
摘要

相似文献

1
An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer.一种抗雄激素抵抗相关基因特征作为一种预后标志物，并通过抑制PLK1提高恩杂鲁胺在前列腺癌中的疗效。
J Transl Med. 2025 Jul 29;23(1):851. doi: 10.1186/s12967-025-06731-9.
2
An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer.一种抗雄激素抵抗相关基因特征作为一种预后标志物，并通过抑制PLK1增加恩杂鲁胺在前列腺癌中的疗效。
J Transl Med. 2025 Apr 27;23(1):480. doi: 10.1186/s12967-025-06457-8.
3
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.恩杂鲁胺与达罗他胺双重疗法在转移性去势敏感性前列腺癌中的匹配调整间接比较
Future Oncol. 2025 Aug;21(19):2459-2469. doi: 10.1080/14796694.2025.2526324. Epub 2025 Jul 14.
4
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
5
Loss of Long Noncoding RNA in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance.前列腺癌中长链非编码 RNA 的缺失增强了雄激素受体的表达和恩杂鲁胺耐药性。
Cancer Res. 2022 Jan 1;82(1):155-168. doi: 10.1158/0008-5472.CAN-20-3845. Epub 2021 Nov 5.
6
Identification of Enzalutamide-Related Genes for Prognosis and Immunotherapy in Prostate Adenocarcinoma.前列腺腺癌中恩杂鲁胺相关基因用于预后评估和免疫治疗的鉴定
Hum Mutat. 2025 Jul 4;2025:9755727. doi: 10.1155/humu/9755727. eCollection 2025.
7
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.监测血浆衍生细胞外囊泡中的糖皮质激素受体作为前列腺癌中雄激素受体信号抑制耐药的标志物。
Cancer Res Commun. 2023 Dec 13;3(12):2531-2543. doi: 10.1158/2767-9764.CRC-23-0362.
8
Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.第二代雄激素受体抑制剂治疗前列腺癌的疗效比较：系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Mar 9;14:1134719. doi: 10.3389/fendo.2023.1134719. eCollection 2023.
9
Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.在接受恩杂鲁胺治疗的转移性去势抵抗性前列腺癌患者中，前列腺特异性抗原在初始雄激素剥夺治疗期间的下降情况对反应和生存的预测作用
In Vivo. 2025 Jul-Aug;39(4):2209-2218. doi: 10.21873/invivo.14016.
10
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.ORIC-101（一种糖皮质激素受体拮抗剂）联合恩扎卢胺治疗转移性去势抵抗性前列腺癌患者的 I 期研究：在恩扎卢胺治疗后进展
Clin Cancer Res. 2024 Mar 15;30(6):1111-1120. doi: 10.1158/1078-0432.CCR-23-3508.

本文引用的文献

1
An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer.一种抗雄激素抵抗相关基因特征作为一种预后标志物，并通过抑制PLK1增加恩杂鲁胺在前列腺癌中的疗效。
J Transl Med. 2025 Apr 27;23(1):480. doi: 10.1186/s12967-025-06457-8.